Inhibitor Therapeutics, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a crossroads, where a sophisticated regulatory and formulation strategy is fighting against a depleted balance sheet. The core of the investment thesis rests on the May 2026 FDA interaction; a positive signal regarding the 505(b)(2) pathway would provide the validation necessary to secure further funding or a strategic partner. However, the 'going concern' qualification in the audit report serves as a stark reminder that the company is operating on a razor-thin margin of error. Ultimately, INTI is a high-risk, high-reward play on a niche orphan drug. The shift toward a licensing-first model is a pragmatic response to its lack of commercial infrastructure, but the success of this pivot depends entirely on the company's ability to maintain liquidity through the next six months. Investors must weigh the potential for a high-margin exit against the very real possibility of total capital loss if the FDA rejects the proposed development pathway or if the pending capital raise fails to materialize.